Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.53 |
| ▸ | TSPO | P30536 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011851 | 0.98 | HCRTR1 (0.51) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL3006496 | 0.95 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL3002255 | 0.93 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL3003390 | 0.93 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL2998136 | 0.93 | HCRTR1 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL3011036 | 0.93 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL3012087 | 0.91 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL3007577 | 0.91 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL3006442 | 0.91 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL3012084 | 0.91 | HCRTR1 (0.53) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288411-B2 | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | claimed |
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-05 | — | — | US | claimed |
| US-8288411-B2 | Pyrrolidines and piperidines as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197733-A1 | PYRROLIDINES AND PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885TSPO 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.